Abstract: The invention provides compositions and methods of modulating and regulating the activity of, expression of, or level of Nr2c2, to thereby modulate T regulatory cell (Treg) differentiation, function, activity, or maturation, or combinations of these biological activities. Such modulation may be useful in methods of treating and preventing cancer, inflammation, and inflammatory diseases, among other diseases, conditions, and illnesses.

Abstract: Described herein are methods and compositions for the induction of the production of regulatory T cells and for the treatment and/or prevention of diseases associated with pathological immune responses, such as inflammatory bowel diseases.

Abstract: A unique type of regulatory T cell has been identified in muscle. These tissue-regenerative Treg cells play a role in regulating wound healing. These cells, as well as agents that control their differentiation and/or activity and agents produced by the cells, can be used to modulate wound healing and the differentiation of muscle cells.

Abstract: The present invention relates to methods and kits for treating, reducing, or preventing autoimmune conditions such as rheumatoid arthritis by administering to a mammal in need thereof an agent that modulates the expression level or biological activity of Toll-like receptor-9 (TLR-9). Also disclosed are screening methods that make use of TLR-9 for the identification of novel therapeutics for autoimmune conditions.

Abstract: The present invention relates to the use of antibodies against glucose-6-phosphate isomerase (GPI) and like protein for diagnosis of arthritis and the use of said protein for treatment of arthritis. It is also aimed at a process for isolating monoclonal antibodies capable of transferring arthritis and antibodies thereof, as well as a method for determining the anti-arthritis potential of a composition.

Abstract: A medication dose calculator and method for comparing an inputted, ordered medication dosage with a known medication dosage range in a database including an input device for inputting a desired drug name, indicating whether the drug is for a child or an adult, an amount of the drugs that are ordered, the body weight or body surface of the patient, and a computing mechanism for determining the dose of the drug to be delivered. The medication dose calculator provides warnings when the inputted amount of drug exceeds the dosage range limits or is incorrect. The medication dose calculator converts an inputted drug unit of measure into a desired unit of measure. In addition, various methods for receiving, recording, storing, transmitting, transferring, and editing information along with various processes utilizing the medication dose calculator are disclosed.

Abstract: A medication dose calculator and method for comparing an inputted, ordered medication dosage with a known medication dosage range in a database including an input device for inputting a desired drug name, indicating whether the drug is for a child or an adult, an amount of the drugs that are ordered, the body weight or body surface of the patient, and a computing mechanism for determining the dose of the drug to be delivered. The medication dose calculator provides warnings when the inputted amount of drug exceeds the dosage range limits or is incorrect. The medication dose calculator converts an inputted drug unit of measure into a desired unit of measure. In addition, various methods for receiving, recording, storing, transmitting, transferring, and editing information along with various processes utilizing the medication dose calculator are disclosed.

Abstract: The present invention relates to methods and kits for treating, reducing, or preventing autoimmune conditions such as rheumatoid arthritis by administering to a mammal in need thereof an agent that modulates the expression level or biological activity of Toll-like receptor-9 (TLR-9). Also disclosed are screening methods that make use of TLR-9 for the identification of novel therapeutics for autoimmune conditions.

Abstract: The present invention relates to the use of antibodies against glucose-6-phosphate isomerase (GPI) and like protein for diagnosis of arthritis and the use of said protein for treatment of arthritis. It is also aimed at a process for isolating monoclonal antibodies capable of transferring arthritis and antibodies thereof, as well as a method for determining the anti-arthritis potential of a composition.

Abstract: A medication dose calculator and method for comparing an inputted, ordered medication dosage with a known medication dosage range in a database including an input device for inputting a desired drug name, indicating whether the drug is for a child or an adult, an amount of the drugs that are ordered, the body weight or body surface of the patient, and a computing mechanism for determining the dose of the drug to be delivered. The medication dose calculator provides warnings when the inputted amount of drug exceeds the dosage range limits or is incorrect. The medication dose calculator converts an inputted drug unit of measure into a desired unit of measure. In addition, various methods for receiving, recording, storing, transmitting, transferring, and editing information along with various processes utilizing the medication dose calculator are disclosed.

Abstract: The present invention relates to the use of antibodies against glucose-6-phosphate isomerase and like protein for diagnosis of arthritis and the use of said protein for treatment of arthritis. It is also aimed at a process for isolating monoclonal antibodies capable of transferring arthritis and antibodies thereof, as well as a method for determining the anti-arthritic potential of a composition.

Abstract: The present invention provides mice which are deficient in the normal expression of one or more MHC class II genes, to mice heterozygous for such deficiency, and to cell lines, preferably pluripotent or totipotent cell lines, which are heterozygous, homozygous or chimeric for such deficiency, as well as to the use of any of the above, especially in situations where the absence of at least one MHC gene, or the normal expression thereof, is desirable.